Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Gel4Med Inc. has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 2 distinct art units. This indicates that while the number of active matters is small, the company is interacting with a different examiner for every one of its 3 pending office actions. The 2 distinct art units involved suggest that the Biotechnology & Pharmaceuticals filings are categorized into two different technical niches.
REYNOLDS, FRED H is the busiest examiner, currently responsible for 1 pending office action. This 1 action represents one-third of the 3 pending office actions total for the portfolio. Since there are 3 distinct examiners, REYNOLDS, FRED H shares the pending workload equally with two other colleagues at the patent office. Managing 3 pending office actions across 3 distinct examiners requires a broad approach to examiner interviews and responses. The 1 pending office action under REYNOLDS, FRED H is a primary focus within the 2 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
| KATAKAM, SUDHAKAR | 1 | 74.7% | +23.3% |
| HELLMAN, KRISTINA M | 1 | 65.3% | +55.3% |
| BOWLES, DAVID PAUL | 1 | 72.7% | +22.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682498 | FILMS FORMED FROM SELF-ASSEMBLING PEPTIDE HYDROGELS | REYNOLDS, FRED H | — |
| 18040380 | ANTIFUNGAL MATRIX FORMED FROM PEPTIDE HYDROGELS | KATAKAM, SUDHAKAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18040398 | TOPICAL AND PARENTERAL USE AND ADMINISTRATION OF SELF-ASSEMBLING AMPHIPHILIC PEPTIDE HYDROGELS | BOWLES, DAVID PAUL | 13d |
| 18682498 | FILMS FORMED FROM SELF-ASSEMBLING PEPTIDE HYDROGELS | REYNOLDS, FRED H | — |
| 18040380 | ANTIFUNGAL MATRIX FORMED FROM PEPTIDE HYDROGELS | KATAKAM, SUDHAKAR | — |
| 18040388 | ANTIMICROBIAL MATRIX FORMED FROM PEPTIDE HYDROGELS | HELLMAN, KRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1613 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682498 | FILMS FORMED FROM SELF-ASSEMBLING PEPTIDE HYDROGELS | REYNOLDS, FRED H | 1613 | §102§103§112 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18040380 | ANTIFUNGAL MATRIX FORMED FROM PEPTIDE HYDROGELS | KATAKAM, SUDHAKAR | 1658 | §102§103§112Other | Final Rejection | — | Pending | Feb 02, 2023 |
| 18040388 | ANTIMICROBIAL MATRIX FORMED FROM PEPTIDE HYDROGELS | HELLMAN, KRISTINA M | 1654 | §102§103§112DP | Non-Final OA | — | Pending | Feb 02, 2023 |
| 18040398 | TOPICAL AND PARENTERAL USE AND ADMINISTRATION OF SELF-ASSEMBLING AMPHIPHILIC PEPTIDE HYDROGELS | BOWLES, DAVID PAUL | 1654 | §102§103DP | Final Rejection | 13d | Pending | Feb 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial